posted on 2023-05-25, 14:20authored byS.M. Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L. Good, Rigel J. Kishton, Biman C. Paria, Zhiya Yu, Marta Bosch-Marce, Nicole M. Bedanova, Chengyu Liu, Michael J. Kruhlak, Nicholas P. Restifo, Raul Vizcardo
Figure S4: Characterization of tumor antigen specific TIL-iPSC clone derived from patient 3784
Funding
HHS | NIH | NCI | Cancer Moonshot (Misión contra el Cáncer)
HHS | NIH | NHLBI | NHLBI Division of Intramural Research (DIR)
History
ARTICLE ABSTRACT
Reprogramming of TIL into iPSC holds great promise for the future treatment of cancer due to their rejuvenated nature and the retention of tumor-specific TCRs. One limitation is the lack of selective and efficient methods for reprogramming tumor-specific T cells from polyclonal TIL. Here we addressed this limitation and present a method to efficiently reprogram TIL into iPSC colonies carrying diverse tumor antigen reactive TCR recombination.